Mechanistic insights into activation and SOCS3-mediated inhibition of myeloproliferative neoplasm-associated JAK2 mutants from biochemical and structural analyses

Biochemical Journal

Volumn 458, Issue 2, 2014, Pages 395-405

  Varghese, Leila N ^a,b   Ungureanu, Daniela ^c   Liau, Nicholas P D ^a,b   Young, Samuel N ^a   Laktyushin, Artem ^a   Hammaren, Henrik ^c   Lucet, Isabelle S ^d   Nicola, Nicos A ^a,b   Silvennoinen, Olli ^c   Babon, Jeffrey J ^a,b   Murphy, James M ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^d MONASH UNIVERSITY   (Australia)

Author keywords

Janus kinase; Phosphorylation; Pseudokinase; Small angle X ray scattering (SAXS); V617F JAK2

Indexed keywords

CATALYTIC DOMAIN; GENETIC PREDISPOSITION TO DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; JANUS KINASE 2; MUTATION, MISSENSE; MYELOPROLIFERATIVE DISORDERS; PROTEIN STRUCTURE, SECONDARY; RECOMBINANT PROTEINS; SCATTERING, SMALL ANGLE; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; X-RAY DIFFRACTION;

EID: 84894272750     PISSN: 02646021     EISSN: 14708728     Source Type: Journal    
DOI: 10.1042/BJ20131516     Document Type: Article

References (67)

1. Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N. et al. (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365, 1054-1061
2. Constantinescu, S. N., Leroy, E., Gryshkova, V., Pecquet, C. and Dusa, A. (2013) Activating Janus kinase pseudokinase domain mutations in myeloproliferative and other blood cancers. Biochem. Soc. Trans. 41, 1048-1054
3. James, C., Ugo, V., Le Couédic, J. P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A. et al. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434, 1144-1148
4. Kralovics, R., Passamonti, F., Buser, A. S., Teo, S. S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M. and Skoda, R. C. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N. Engl. J. Med. 352, 1779-1790
5. Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S. et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7, 387-397
6. Zhao, R., Xing, S., Li, Z., Fu, X., Li, Q., Krantz, S. B. and Zhao, Z. J. (2005) Identification of an acquired JAK2 mutation in polycythemia vera. J. Biol. Chem. 280, 22788-22792
7. Harpur, A. G., Andres, A. C., Ziemiecki, A., Aston, R. R. and Wilks, A. F. (1992) JAK2, a third member of the JAK family of protein tyrosine kinases. Oncogene 7, 1347-1353
8. Lucet, I. S., Fantino, E., Styles, M., Bamert, R., Patel, O., Broughton, S. E., Walter, M., Burns, C. J., Treutlein, H., Wilks, A. F. and Rossjohn, J. (2006) The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 107, 176-183
9. Boggon, T. J., Li, Y., Manley, P. W. and Eck, M. J. (2005) Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood 106, 996-1002
10. Williams, N. K., Bamert, R. S., Patel, O., Wang, C., Walden, P. M., Wilks, A. F., Fantino, E., Rossjohn, J. and Lucet, I. S. (2009) Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains. J. Mol. Biol. 387, 219-232
11. Sanz, A., Ungureanu, D., Pekkala, T., Ruijtenbeek, R., Touw, I. P., Hilhorst, R. and Silvennoinen, O. (2011) Analysis of Jak2 catalytic function by peptide microarrays: the role of the JH2 domain and V617F mutation. PLoS ONE 6, e18522
12. Ungureanu, D., Wu, J., Pekkala, T., Niranjan, Y., Young, C., Jensen, O. N., Xu, C. F., Neubert, T. A., Skoda, R. C., Hubbard, S. R. and Silvennoinen, O. (2011) The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling. Nat. Struct. Mol. Biol. 18, 971-976
13. Toms, A. V., Deshpande, A., McNally, R., Jeong, Y., Rogers, J. M., Kim, C. U., Gruner, S. M., Ficarro, S. B., Marto, J. A., Sattler, M. et al. (2013) Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases. Nat. Struct. Mol. Biol. 20, 1221-1223
14. Bandaranayake, R. M., Ungureanu, D., Shan, Y., Shaw, D. E., Silvennoinen, O. and Hubbard, S. R. (2012) Crystal structures of the JAK2 pseudokinase domain and the pathogenic mutant V617F. Nat. Struct. Mol. Biol. 19, 754-759
15. Silvennoinen, O., Ungureanu, D., Niranjan, Y., Hammaren, H., Bandaranayake, R. and Hubbard, S. R. (2013) New insights into the structure and function of the pseudokinase domain in JAK2. Biochem. Soc. Trans. 41, 1002-1007
16. Starr, R., Willson, T. A., Viney, E. M., Murray, L. J., Rayner, J. R., Jenkins, B. J., Gonda, T. J., Alexander, W. S., Metcalf, D., Nicola, N. A. and Hilton, D. J. (1997) A family of cytokine-inducible inhibitors of signalling. Nature 387, 917-921
17. Sasaki, A., Yasukawa, H., Suzuki, A., Kamizono, S., Syoda, T., Kinjyo, I., Sasaki, M., Johnston, J. A. and Yoshimura, A. (1999) Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells 4, 339-351
18. Yasukawa, H., Misawa, H., Sakamoto, H., Masuhara, M., Sasaki, A., Wakioka, T., Ohtsuka, S., Imaizumi, T., Matsuda, T., Ihle, J. N. and Yoshimura, A. (1999) The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. EMBO J. 18, 1309-1320
19. Zhang, J. G., Farley, A., Nicholson, S. E., Willson, T. A., Zugaro, L. M., Simpson, R. J., Moritz, R. L., Cary, D., Richardson, R., Hausmann, G. et al. (1999) The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc. Natl. Acad. Sci. U.S.A. 96, 2071-2076
20. Capello, D., Deambrogi, C., Rossi, D., Lischetti, T., Piranda, D., Cerri, M., Spina, V., Rasi, S., Gaidano, G. and Lunghi, M. (2008) Epigenetic inactivation of suppressors of cytokine signalling in Philadelphia-negative chronic myeloproliferative disorders. Br. J. Haematol. 141, 504-511
21. Chaligné, R., Tonetti, C., Besancenot, R., Marty, C., Kiladjian, J. J., Socié, G., Bordessoule, D., Vainchenker, W., Giraudier, S. and French Intergroup for MPD (2009) SOCS3 inhibits TPO-stimulated, but not spontaneous, megakaryocytic growth in primary myelofibrosis. Leukemia 23, 1186-1190
22. Fourouclas, N., Li, J., Gilby, D., Campbell, P., Beer, P., Boyd, E., Goodeve, A., Bareford, D., Harrison, C., Reilly, J. et al. (2008) Methylation of the suppressor of cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders. Haematologica 93, 1635-1644
23. Jost, E., do Ó, N., Dahl, E., Maintz, C. E., Jousten, P., Habets, L., Wilop, S., Herman, J. G., Osieka, R. and Galm, O. (2007) Epigenetic alterations complement mutation of JAK2 tyrosine kinase in patients with BCR/ABL-negative myeloproliferative disorders. Leukemia 21, 505-510
24. Teofili, L., Martini, M., Cenci, T., Guidi, F., Torti, L., Giona, F., Foa, R., Leone, G. and Larocca, L. M. (2008) Epigenetic alteration of SOCS family members is a possible pathogenetic mechanism in JAK2 wild type myeloproliferative diseases. Int. J. Cancer 123, 1586-1592
25. Bock, O., Hussein, K., Brakensiek, K., Buhr, T., Schlue, J., Wiese, B. and Kreipe, H. (2007) The suppressor of cytokine signalling-1 (SOCS-1) gene is overexpressed in Philadelphia chromosome negative chronic myeloproliferative disorders. Leuk. Res. 31, 799-803
26. Kralovics, R., Teo, S. S., Buser, A. S., Brutsche, M., Tiedt, R., Tichelli, A., Passamonti, F., Pietra, D., Cazzola, M. and Skoda, R. C. (2005) Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood 106, 3374-3376
27. Haan, S., Wüller, S., Kaczor, J., Rolvering, C., Nöcker, T., Behrmann, I. and Haan, C. (2009) SOCS-mediated downregulation of mutant Jak2 (V617F, T875N and K539L) counteracts cytokine-independent signaling. Oncogene 28, 3069-3080
28. Elliott, J., Suessmuth, Y., Scott, L. M., Nahlik, K., McMullin, M. F., Constantinescu, S. N., Green, A. R. and Johnston, J. A. (2009) SOCS3 tyrosine phosphorylation as a potential bio-marker for myeloproliferative neoplasms associated with mutant JAK2 kinases. Haematologica 94, 576-580
29. Hookham, M. B., Elliott, J., Suessmuth, Y., Staerk, J., Ward, A. C., Vainchenker, W., Percy, M. J., McMullin, M. F., Constantinescu, S. N. and Johnston, J. A. (2007) The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood 109, 4924-4929
30. Kershaw, N. J., Murphy, J. M., Liau, N. P., Varghese, L. N., Laktyushin, A., Whitlock, E. L., Lucet, I. S., Nicola, N. A. and Babon, J. J. (2013) SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition. Nat. Struct. Mol. Biol. 20, 469-476
31. Babon, J. J. and Murphy, J. M. (2013) In vitro JAK kinase activity and inhibition assays. Methods Mol. Biol. 967, 39-55
32. Murphy, J. M., Zhang, Q., Young, S. N., Reese, M. L., Bailey, F. P., Eyers, P. A., Ungureanu, D., Hammaren, H., Silvennoinen, O., Varghese, L. N. et al. (2014) A robust methodology to subclassify pseudokinases based on their nucleotide binding properties. Biochem. J. 457, 323-334
33. Babon, J. J., Yao, S., DeSouza, D. P., Harrison, C. F., Fabri, L. J., Liepinsh, E., Scrofani, S. D., Baca, M. and Norton, R. S. (2005) Secondary structure assignment of mouse SOCS3 by NMR defines the domain boundaries and identifies an unstructured insertion in the SH2 domain. FEBS J. 272, 6120-6130
34. Babon, J. J., Kershaw, N. J., Murphy, J. M., Varghese, L. N., Laktyushin, A., Young, S. N., Lucet, I. S., Norton, R. S. and Nicola, N. A. (2012) Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity 36, 239-250
35. Babon, J. J., Sabo, J. K., Soetopo, A., Yao, S., Bailey, M. F., Zhang, J. G., Nicola, N. A. and Norton, R. S. (2008) The SOCS box domain of SOCS3: structure and interaction with the elonginBC-cullin5 ubiquitin ligase. J. Mol. Biol. 381, 928-940
36. Saharinen, P., Vihinen, M. and Silvennoinen, O. (2003) Autoinhibition of Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol. Biol. Cell 14, 1448-1459
37. Kirby, N. M., Mudie, S. T., Hawley, A. M., Cookson, D. J., Mertens, H. D. T., Cowieson, N. and Samardzic-Boban, V. (2013) A low-background-intensity focusing small-angle X-ray scattering undulator beamline. J. Appl. Crystallogr. 46, 1670-1680
38. Murphy, J. M., Czabotar, P. E., Hildebrand, J. M., Lucet, I. S., Zhang, J. G., Alvarez-Diaz, S., Lewis, R., Lalaoui, N., Metcalf, D., Webb, A. I. et al. (2013) The pseudokinase MLKL mediates necroptosis via a molecular switch mechanism. Immunity 39, 443-453
39. Murphy, J. M., Lucet, I. S., Hildebrand, J. M., Tanzer, M. C., Young, S. N., Sharma, P., Lessene, G., Alexander, W. S., Babon, J. J., Silke, J. and Czabotar, P. E. (2014) Insights into the evolution of divergent nucleotide-binding mechanisms among pseudokinases revealed by crystal structures of human and mouse MLKL. Biochem. J. 457, 369-377
40. Konarev, P. V., Petoukhov, M. V., Volkov, V. V. and Svergun, D. I. (2006) ATSAS 2.1, a program package for small-angle scattering data analysis. J. Appl. Crystallogr. 39, 277-286
41. Konarev, P. V., Volkov, V. V., Sokolova, A. V., Koch, M. H. J. and Svergun, D. I. (2003) PRIMUS: a Windows PC-based system for small-angle scattering data analysis. J. Appl. Crystallogr. 36, 1277-1282
42. Svergun, D. I. (1992) Determination of the regularization parameter in indirect-transform methods using perceptual criteria. J. Appl. Crystallogr. 25, 495-503
43. Petoukhov, M. V. and Svergun, D. I. (2005) Global rigid body modeling of macromolecular complexes against small-angle scattering data. Biophys. J. 89, 1237-1250
44. V617F. J. Biol. Chem. 283, 5258-5266
45. Pelletier, S., Gingras, S., Funakoshi-Tago, M., Howell, S. and Ihle, J. N. (2006) Two domains of the erythropoietin receptor are sufficient for Jak2 binding/activation and function. Mol. Cell. Biol. 26, 8527-8538
46. V617F-mediated transformation. Proc. Natl. Acad. Sci. U.S.A. 102, 18962-18967
47. Argetsinger, L. S., Kouadio, J. L., Steen, H., Stensballe, A., Jensen, O. N. and Carter-Su, C. (2004) Autophosphorylation of JAK2 on tyrosines 221 and 570 regulates its activity. Mol. Cell. Biol. 24, 4955-4967
48. Feener, E. P., Rosario, F., Dunn, S. L., Stancheva, Z. and Myers, M. G. (2004) Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling. Mol. Cell. Biol. 24, 4968-4978
49. Kershaw, N. J., Murphy, J. M., Lucet, I. S., Nicola, N. A. and Babon, J. J. (2013) Regulation of Janus kinases by SOCS proteins. Biochem. Soc. Trans. 41, 1042-1047
50. Babon, J. J. and Nicola, N. A. (2012) The biology and mechanism of action of suppressor of cytokine signaling 3. Growth Factors 30, 207-219
51. Saharinen, P., Takaluoma, K. and Silvennoinen, O. (2000) Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol. Cell. Biol. 20, 3387-3395
52. Koppikar, P., Bhagwat, N., Kilpivaara, O., Manshouri, T., Adli, M., Hricik, T., Liu, F., Saunders, L. M., Mullally, A., Abdel-Wahab, O. et al. (2012) Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature 489, 155-159
53. V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood 111, 3751-3759
54. Zhao, L., Ma, Y., Seemann, J. and Huang, L. J. (2010) A regulating role of the JAK2 FERM domain in hyperactivation of JAK2(V617F). Biochem. J. 426, 91-98
55. V617F requires an intact SH2-like domain for constitutive activation and induction of a myeloproliferative disease in mice. Blood 116, 4600-4611
56. Lucet, I. S., Babon, J. J. and Murphy, J. M. (2013) Techniques to examine nucleotide binding by pseudokinases. Biochem. Soc. Trans. 41, 975-980
57. Scott, L. M., Tong, W., Levine, R. L., Scott, M. A., Beer, P. A., Stratton, M. R., Futreal, P. A., Erber, W. N., McMullin, M. F., Harrison, C. N. et al. (2007) JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N. Engl. J. Med. 356, 459-468
58. Martinez-Aviles, L., Besses, C., Alvarez-Larran, A., Cervantes, F., Hernandez-Boluda, J. C. and Bellosillo, B. (2007) JAK2 exon 12 mutations in polycythemia vera or idiopathic erythrocytosis. Haematologica 92, 1717-1718
59. Lee, J. W., Kim, Y. G., Soung, Y. H., Han, K. J., Kim, S. Y., Rhim, H. S., Min, W. S., Nam, S. W., Park, W. S., Lee, J. Y. et al. (2006) The JAK2 V617F mutation in de novoacute myelogenous leukemias. Oncogene 25, 1434-1436
60. Kratz, C. P., Böll, S., Kontny, U., Schrappe, M., Niemeyer, C. M. and Stanulla, M. (2006) Mutational screen reveals a novel JAK2 mutation, L611S, in a child with acute lymphoblastic leukemia. Leukemia 20, 381-383
61. Nussenzveig, R. H., Burjanivova, T., Salama, M. E., Ogilvie, N. W., Marcinek, J., Plank, L., Agarwal, A. M., Perkins, S. L. and Prchal, J. T. (2012) Detection of JAK2 mutations in paraffin marrow biopsies by high resolution melting analysis: identification of L611S alone and in cis with V617F in polycythemia vera. Leuk. Lymphoma 53, 2479-2486
62. Schnittger, S., Bacher, U., Kern, W., Schröder, M., Haferlach, T. and Schoch, C. (2006) Report on two novel nucleotide exchanges in the JAK2 pseudokinase domain: D620E and E627E. Leukemia 20, 2195-2197
63. Grunebach, F., Bross-Bach, U., Kanz, L. and Brossart, P. (2006) Detection of a new JAK2 D620E mutation in addition to V617F in a patient with polycythemia vera. Leukemia 20, 2210-2211
64. Bercovich, D., Ganmore, I., Scott, L. M., Wainreb, G., Birger, Y., Elimelech, A., Shochat, C., Cazzaniga, G., Biondi, A., Basso, G. et al. (2008) Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome. Lancet 372, 1484-1492
65. Mullighan, C. G., Zhang, J., Harvey, R. C., Collins-Underwood, J. R., Schulman, B. A., Phillips, L. A., Tasian, S. K., Loh, M. L., Su, X., Liu, W. et al. (2009) JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. U.S.A. 106, 9414-9418
66. Zhang, J. H., Mullighan, C. G., Harvey, R. C., Wu, G., Chen, X., Edmonson, M., Buetow, K. H., Carroll, W. L., Chen, I. M., Devidas, M. et al. (2011) Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 118, 3080-3087
67. Kearney, L., De Castro, D. G., Yeung, J., Procter, J., Horsley, S. W., Eguchi-Ishimae, M., Bateman, C. M., Anderson, K., Chaplin, T., Young, B. D. et al. (2009) Specific JAK2 mutation (JAK2R683) and multiple gene deletions in Down syndrome acute lymphoblastic leukemia. Blood 113, 646-648